Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


ASCO 2023: TRIMM-2 Update Supports Steroid-Sparing Regimen for Resistant Myeloma

By: Julia Fiederlein Cipriano
Posted: Monday, June 5, 2023

According to Bhagirathbhai R. Dholaria, MBBS, of Vanderbilt University Medical Center, Nashville, and colleagues, the T-cell–redirecting bispecific antibody talquetamab in combination with the anti-CD38 monoclonal antibody daratumumab demonstrated deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. The updated results from the TRIMM-2 trial, which were presented during the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (Abstract 8003), did not reveal any new safety signals.

A total of 65 patients received 1,800 mg of subcutaneous daratumumab in combination with either a recommended phase II dose of 0.4 mg/kg weekly or 0.8 mg/kg biweekly subcutaneous talquetamab with step-up dosing. In this population, prior treatments included anti-CD38 (88%), anti–B-cell maturation antigen (BCMA; 54%), bispecific antibody (25%), and anti-BCMA chimeric antigen receptor T-cell (17%) therapy. Follow-up data were provided for a median of 11.5 months.

All patients experienced at least one adverse event; cytokine-release syndrome (78%), dysgeusia (75%), dry mouth (55%), anemia (52%), fatigue (45%), and skin exfoliation (45%) were reported most frequently. Infections and neutropenia occurred in 63% and 38% of patients, respectively. A total of 85% of patients demonstrated post-baseline immunoglobulin G levels of less than 500 mg/dL; of this population, 32% received intravenous immunoglobulin. Immune effector cell–associated neurotoxicity syndrome was reported in 5% of patients.

Across the recommended phase II doses, the objective response rate was 78% in the overall population and 100% in those who had not undergone prior anti-CD38 therapy. In patients who were exposed or refractory to prior treatment, the objective response rates were 75% and 76% with anti-CD38 therapy, 74% and 64% with anti-BCMA therapy, and 75% and 75% with bispecific antibody therapy, respectively. At 12 months, 86% of responders continued to respond. The median duration of progression-free survival was 19.4 months; the 12-month progression-free and overall survival rates were 76% and 93%, respectively.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.